aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

aTyr Pharma, Inc.NASDAQ: ATYR

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $190K. Over 3 fiscal years it compounded at -73.7% a year.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 6 analysts of $3.86M (+1928.9%) for the fiscal year ending Dec 2026, a step up from the -19.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$190K-19.1% YoY
LTMMar 2026
$190K— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-19.1%+1928.9%+1948.1 pp
3-year CAGR-73.7%+173.0%+246.7 pp
5-year CAGR+293.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
190K USD
Year-over-year change
-19.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ATYR compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Over three fiscal years its annual growth of -73.7% compares with a peer median of +9.6%.
ATYR Competitors
Revenue for ATYR and competitors
Company Period LTM YoY 3-year CAGR
DTILPrecision BioSciences, Inc.LTM Mar 2026$45.07M USD-11.9%+10.9%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$18.36M CAD+3.3%+8.2%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$3.93M USD+160.5%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$190K USD—-73.7%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 USD——
ALXOALX Oncology Holdings Inc.LTM Mar 2026$0 USD——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$0 USD——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 USD——
Peer median (excluding ATYR) —+3.3%+9.6%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue010.39M353K235K190K
Cost of Revenue1.3M1.7M001.55M
Gross Profit(1.3M)8.69M353K235K(1.36M)
Gross Margin—83.7%100.0%100.0%-717.4%
Research & Development23.26M42.81M42.29M54.37M60.22M
Selling, General & Admin10.75M12.29M12.98M13.78M17.6M
Operating Expenses32.71M55.1M55.27M68.15M76.26M
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
EBITDA(32.47M)(43.65M)(47.66M)(62.48M)(72.57M)
EBITDA Margin—-420.3%-13500.3%-26588.1%-38192.1%
Operating Income(34.02M)(46.4M)(54.92M)(67.91M)(77.63M)
Operating Margin—-446.8%-15557.8%-28899.6%-40856.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses238K1.06M4.52M3.89M3.51M
Income Before Tax(33.78M)(45.34M)(50.4M)(64.02M)(74.12M)
Pre-Tax Margin—-436.6%-14276.8%-27243.4%-39009.5%
Income Tax Expense00000
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Net Margin—-436.5%-14274.5%-27243.8%-39009.5%
EPS (Basic)(1.77)(1.60)(0.94)(0.86)(0.80)
EPS (Diluted)(1.77)(1.60)(0.94)(0.86)(0.80)
Weighted Avg Shares19.08M28.42M53.61M74.26M92.99M
Weighted Avg Shares (Diluted)19.08M28.42M53.61M74.26M92.99M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.